Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool below to find open protocols for your type of cancer. To learn more about eligibility and participation call 877-789-6100.

Search by conditions: 

Click a protocol # to view extended details on a particular clinical trial.

Protocol #DescriptionPhase
13-251A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the Fibroblast Growth Factor Receptor (FGFR) 1, 2 or 3 Genes  (View details on clinicaltrial.gov)Phase I
12-344A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction  (View details on clinicaltrial.gov)Phase III
12-477A Randomized, Phase II, Placebo-Controlled Study of GDC-0068, an Inhibitor to AKT, in Combination with Fluoropyrimidine Plus Oxaliplatin in Patients with Locally Advanced to Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma  (View details on clinicaltrial.gov)Phase II
14-071An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma  (View details on clinicaltrial.gov)Phase II
09-457Phase II Trial of CAPOX + Bevacizumab + Trastuzumab for Patients with HER2-Positive Metastatic Esophagogastric Cancer  (View details on clinicaltrial.gov)Phase II
10-434Randomized Study of Early Palliative Care Integrated with Standard Oncology Care versus Standard Oncology Care Alone in Patients with Advanced Lung and Non-colorectal Gastrointestinal Malignancies  (View details on clinicaltrial.gov)N/A
12-401Randomized, Double-Blind, Placebo Controlled Phase II Study of FOLFOX +/- Ziv-Aflibercept in Patients With Advanced Esophageal and Gastric Cancer  (View details on clinicaltrial.gov)Phase II
13-196Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With or Without Trastuzumab in Patients With 'Traditional' and 'Non-Traditional' HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy  (View details on clinicaltrial.gov)Phase II
11-163RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma  (View details on clinicaltrial.gov)Phase III
9 clinical trials listed.

Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.